Sorafenib;Sorafenib

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 37, 2010, Pages 1819-1822

  Hansen, A ^a   Eschenhagen, T ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

sorafenib; tyrosine kinase inhibitor

Indexed keywords

CD135 ANTIGEN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN RET; SORAFENIB; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ALOPECIA; CANCER INVASION; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; HYPOPHOSPHATEMIA; IC 50; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PRURITUS; REVIEW; TUMOR GROWTH; ANALOGS AND DERIVATIVES; APOPTOSIS; DRUG EFFECTS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; HUMANS; HYPOPHOSPHATEMIA; PROTEIN KINASE INHIBITORS; PYRIDINES; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 77956668289     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1247869     Document Type: Review

References (13)

1. Cheng A L., Kang Y K., Chen Z, Tsao C J., Qin S, Kim J S. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009 10 25-34
2. Escudier B, Eisen T, Stadler W M., Szczylik C, Oudard S, Siebels M, et al, TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 125-134
3. Escudier B, Eisen T, Stadler W M., Szczylik C, Oudard S, Staehler M et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009 27 3312-3318
4. Escudier B, Szczylik C, Hutson T E., Demkow T, Staehler M, Rolland F et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 27 1280-1289
5. Fachinformation Sorafenib. Stand Juni 2009
6. Force T, Krause D S., Van Etten R A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007 7 332-344 (Pubitemid 46652481)
7. Hauschild A, Agarwala S S., Trefzer U, Hogg D, Robert C, Hersey P et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009 27 2823-2830
8. Llovet J M., Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J F., SHARP I nvestigators Study Group et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 359 378-390
9. May D, Gilon D, Djonov V, Itin A, Lazarus A, Gordon O et al. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci U S A 2008 105 282-287
10. McDermott D F., Sosman J A., Gonzalez R, Hodi F S., Linette G P., Richards J et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008 26 2178-2185
11. Therasse P, Arbuck S G., Eisenhauer E A., Wanders J, Kaplan R S., Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 205-216
12. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith R A. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006 5 835-844
13. Wilhelm S M., Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. BAY 439006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 64 7099-7109